Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation
Status:
Terminated
Trial end date:
2018-06-12
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well midostaurin and decitabine work in treating older
patients with newly diagnosed acute myeloid leukemia and FLT3 mutations. Midostaurin and
decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth.